Paediatric Sleep Disorders — Evidence-Based Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sleep disorders in children and adolescents are common, underdiagnosed, and significantly impact neurodevelopment, academic performance, mental health, metabolic health, and quality of life for both the child and their family. Healthy sleep is not simply a passive state — it is an active, physiologically essential process during which the brain consolidates learning, regulates hormones (including growth hormone, secreted predominantly during slow-wave sleep), processes emotional experiences, and clears metabolic waste products through the glymphatic system.

Sleep architecture changes substantially across childhood: neonates spend up to 50% of sleep time in rapid eye movement (REM) sleep (compared with 20–25% in adults), reflecting its role in synaptic development and neural circuit maturation. Total sleep requirement decreases progressively from approximately 14–17 hours in newborns to 9–11 hours in school-age children and 8–10 hours in adolescents. Adolescent circadian biology is characterised by a physiological phase delay — a genuine biological shift in the sleep-wake cycle towards later sleep onset and later morning wake time — distinct from volitional "staying up late".

Paediatric sleep disorders are classified under the International Classification of Sleep Disorders, 3rd edition (ICSD-3), into six major categories: insomnias, sleep-related breathing disorders (including obstructive sleep apnoea), central disorders of hypersomnolence (narcolepsy), circadian rhythm sleep-wake disorders (CRSD), parasomnias, and sleep-related movement disorders. Each category has distinct diagnostic criteria, developmental considerations, and evidence-based management pathways.

Diagnosis draws on clinical history (including detailed sleep diary), validated questionnaires (Paediatric Sleep Questionnaire, Epworth Sleepiness Scale for older children), actigraphy (wrist-worn accelerometer recording rest-activity rhythms over days to weeks, highly useful for CRSD), and overnight polysomnography (PSG) — the gold standard for obstructive sleep apnoea and narcolepsy.

Paediatric sleep medicine is a multidisciplinary field involving paediatric respiratory physicians, neurologists, ENT surgeons, clinical psychologists, orthodontists, and dietitians, reflecting the diverse aetiology and treatment landscape of sleep disorders in the young.

The major paediatric sleep disorders evaluated and managed by specialists include:

• Obstructive sleep apnoea (OSA): Characterised by recurrent episodes of upper airway obstruction during sleep, causing apnoea or hypopnoea (partial obstruction), oxygen desaturation, sleep fragmentation, and arousal. In children, the peak age is 2–8 years, and adenotonsillar hypertrophy is the most common cause. OSA affects 1–4% of children. Diagnosis requires overnight PSG: apnoea-hypopnoea index (AHI) >1 event per hour is abnormal in children (compared with >5 in adults). Consequences of untreated paediatric OSA include neurobehavioural impairment (inattention, hyperactivity, learning difficulties), growth impairment, and cardiovascular and metabolic sequelae.
• Parasomnias: Disorders of arousal or behaviours during sleep, subdivided by sleep stage:
  • NREM parasomnias (disorders of arousal): Sleep terrors (night terrors) — abrupt partial arousal from slow-wave sleep with intense autonomic activation, vocalisation, apparent fear, and amnesia for the event — occur most commonly aged 4–12 years. Sleepwalking (somnambulism) — complex motor behaviours during NREM sleep, with the child ambulant but unresponsive and amnesic — peaks at 8–12 years. Both are developmentally normal variants of immature NREM arousal regulation, typically resolving spontaneously with age.
  • REM parasomnias: Nightmares — vivid, frightening dreams occurring during REM sleep, with immediate recall on awakening — are common (affecting up to 30% of children) and developmentally appropriate in preschool and early school-age children. Persistent nightmares in older children may indicate anxiety, PTSD, or medication effects.
• Circadian rhythm sleep-wake disorders (CRSD) in adolescents: The most common is delayed sleep-wake phase disorder (DSWPD), in which the circadian clock is shifted 2–6 hours later than societal norms. The adolescent cannot fall asleep until 1–3 am and experiences excessive sleepiness in the morning. DSWPD is amplified by artificial light exposure (particularly blue light from screens) in the evening, which suppresses endogenous melatonin secretion. Actigraphy and dim-light melatonin onset (DLMO) testing confirm the diagnosis.
• Chronic insomnia (behavioural insomnia of childhood): Difficulty initiating or maintaining sleep in the context of inappropriate sleep associations (e.g., requiring parental presence to fall asleep — limit-setting type) or sleep-onset dependency on feeding or rocking. Insomnia in adolescents shares features with adult insomnia: cognitive hyperarousal, conditioned arousal to the sleep environment, and perpetuating behaviours (excessive time in bed, daytime napping, screen use at bedtime).
• Narcolepsy type 1 (narcolepsy with cataplexy): A chronic neurological disorder of excessive daytime sleepiness caused by selective loss of orexin (hypocretin)-producing neurons in the hypothalamus, resulting in undetectable or very low CSF orexin levels. Strongly associated with HLA-DQB1*06:02 (present in >95% of cases, versus 12–38% of the general population). Cataplexy — sudden loss of muscle tone triggered by strong positive emotions (laughter, excitement) — is pathognomonic. Sleep paralysis and hypnagogic hallucinations complete the classic tetrad.
• Restless legs syndrome (RLS) and periodic limb movement disorder (PLMD): RLS in children presents as an urge to move the legs, worse in the evening and at night, relieved by movement. Children may describe it as "creepy-crawly," "tickly," or "bugs crawling inside the legs." RLS in children is strongly associated with iron deficiency (serum ferritin <50 ng/mL) and ADHD. PLMD — stereotyped periodic limb movements during sleep causing arousals and daytime fatigue — is diagnosed by PSG.

Many childhood sleep concerns can be addressed in primary care; however, specialist sleep assessment is indicated in the following scenarios:

• Suspected OSA: Any child with habitual snoring (>3 nights per week) plus any of: observed apnoeas (breathing pauses during sleep reported by parents), laboured or mouth breathing during sleep, restless sleep, nocturnal sweating, enuresis (bedwetting), morning headaches, difficulty waking in the morning, daytime sleepiness, or neurobehavioural symptoms (inattention, hyperactivity, learning difficulties) should be referred for ENT assessment and consideration of overnight PSG. Children with Down syndrome, craniofacial abnormalities, neuromuscular disease, or obesity are at significantly elevated OSA risk and should have low-threshold referral.
• Parasomnias requiring investigation: Most NREM parasomnias (sleep terrors, sleepwalking) in children are benign and self-limiting; specialist referral is warranted if events are very frequent (nightly or multiple times nightly), prolonged (>30 minutes), associated with risk of injury, stereotyped in a way that suggests nocturnal seizures, or accompanied by daytime sleepiness suggesting a primary sleep disorder. Video-PSG is the key diagnostic tool when nocturnal epilepsy must be excluded.
• Suspected CRSD: Adolescents who consistently cannot fall asleep until after midnight, have severe morning sleepiness affecting school attendance, and show a normalised sleep pattern at weekends and during school holidays should be assessed for DSWPD with a 2-week actigraphy recording, sleep diary, and DLMO testing if available.
• Suspected narcolepsy: Children or adolescents with excessive daytime sleepiness not explained by insufficient sleep duration, particularly if accompanied by cataplexy, should be urgently referred for overnight PSG followed by Multiple Sleep Latency Test (MSLT) — the diagnostic gold standard for narcolepsy (mean sleep latency <8 minutes with >=2 sleep-onset REM periods). The diagnosis of narcolepsy is important to establish prior to initiating any REM-suppressing medications.
• RLS and iron deficiency: Children with evening leg discomfort, restless sleep, growing pains that specifically worsen at night, and significant ADHD-type symptoms should have ferritin measured. Ferritin below 50 ng/mL warrants oral iron supplementation as first-line treatment for RLS. Persistent RLS despite iron repletion requires sleep specialist referral.

Treatment in paediatric sleep medicine is condition-specific and incorporates behavioural, pharmacological, and surgical strategies as appropriate:

• OSA — Adenotonsillectomy (AT): Surgical removal of the adenoids and tonsils is the first-line treatment for paediatric OSA when adenotonsillar hypertrophy is the primary cause. The landmark CHAT (Childhood Adenotonsillectomy Trial) randomised 464 children aged 5–9 years with mild-to-moderate OSA to early adenotonsillectomy or watchful waiting. AT reduced the mean apnoea-hypopnoea index by 84% (from 4.9 to 0.7 events/hour) and significantly improved polysomnographic measures, quality of life, and neurobehavioural outcomes. However, 27% of children in the surgery group had residual OSA on post-operative PSG, highlighting the importance of post-operative confirmation of cure 6–8 weeks post-surgery. Children with residual OSA require additional treatment (CPAP, mandibular advancement device, or weight management).
• OSA — CPAP: Continuous positive airway pressure via a nasal or full-face mask is the treatment of choice for children who are not surgical candidates, have residual OSA after AT, or have obesity-related OSA. CPAP titration (typically during a PSG titration night) determines the effective therapeutic pressure. Auto-titrating CPAP (APAP) is increasingly used, particularly in children with comorbid obesity. CPAP adherence is the main challenge in children; child-specific mask fitting, family-centred desensitisation programmes, and adherence download reviews at 4–6 weekly intervals are essential.
• Parasomnias — management: NREM parasomnias (sleep terrors, sleepwalking) are primarily managed with parental education and safety measures (stairgate, door alarms, removing hazards). Scheduled awakenings — waking the child 15–30 minutes before the typical event time — are effective in reducing sleep terror frequency. Sleep hygiene optimisation (regular bedtime, adequate total sleep time, avoidance of sleep deprivation — a potent precipitant of NREM parasomnias) is essential. Low-dose melatonin (0.5–1 mg 30 minutes before bedtime) improves sleep onset in children with co-occurring sleep initiation difficulties. Pharmacotherapy (clonazepam, tricyclic antidepressants) is rarely indicated in children and reserved for severe cases with injury risk.
• CRSD — Melatonin and light therapy: For DSWPD in adolescents, the combination of low-dose melatonin (0.5 mg, taken 5–6 hours before the desired sleep onset time — the phase-advancing pharmacodynamic window) and morning bright light therapy (10,000 lux white light box for 30 minutes upon waking) advances the circadian clock. Strict morning wake times (including weekends) and blue-light-blocking strategies in the evening (blue-light-filter glasses, night mode on screens, ceasing screen use 1–2 hours before target bedtime) are essential adjuncts. Social jet lag reduction — aligning weekday and weekend sleep times — is critically important.
• Insomnia — CBT-I-A: Cognitive Behavioural Therapy for Insomnia adapted for Adolescents (CBT-I-A) is the evidence-based first-line treatment for chronic insomnia in adolescents, superior to sleep medication in multiple trials. Core components include: sleep restriction therapy (restricting time in bed to consolidate sleep drive), stimulus control (bed for sleep only; arising if awake for >20 minutes), sleep hygiene education, relaxation techniques (progressive muscle relaxation, mindfulness), and cognitive restructuring of maladaptive beliefs about sleep.
• Narcolepsy — pharmacological management: Excessive daytime sleepiness is treated with sodium oxybate (Xyrem) — the most effective agent for both EDS and cataplexy in narcolepsy type 1, licensed from age 7 in some jurisdictions — or modafinil (off-label in children under 18 in many countries). Cataplexy is additionally managed with venlafaxine, fluoxetine, or sodium oxybate. Structured nap schedules (2 x 15–20 minute planned naps at school) significantly reduce EDS. Sleep-wake education and DVLA/driving guidance are critical at age-appropriate transition.
• RLS — iron supplementation: In children with serum ferritin <50 ng/mL, oral iron supplementation (ferrous sulphate 3 mg/kg elemental iron per day with vitamin C to enhance absorption) is the first-line treatment. Ferritin should be rechecked after 3 months. Dietary advice (red meat, legumes, leafy vegetables; avoid tea with meals) complements supplementation. Dopaminergic agents (ropinirole, pramipexole) used in adult RLS are not recommended in children due to risk of augmentation and limited paediatric evidence.

Recognition and effective treatment of paediatric sleep disorders delivers substantial benefits across multiple developmental domains:

• Neurocognitive and academic improvement after OSA treatment: The CHAT trial demonstrated significant improvements in attention and executive function (measured by the NEPSY-II standardised battery) in children treated with AT compared with watchful waiting, as well as improved quality of life for both child and parent. Observational studies consistently link untreated childhood OSA with impaired working memory, processing speed, and academic achievement — all of which improve with successful OSA treatment.
• Behavioural and mental health benefits: Children with undiagnosed OSA or chronic insomnia frequently present with ADHD-like inattention, hyperactivity, and emotional dysregulation — symptoms that improve significantly with sleep disorder treatment, sometimes reducing or eliminating the need for ADHD medication. Sleep disruption is bidirectionally linked to anxiety and depression in adolescents; treating insomnia via CBT-I-A has demonstrated significant reductions in anxiety and depressive symptom severity.
• Growth and metabolic improvement: Growth hormone is predominantly secreted during slow-wave sleep; children with severe OSA have impaired growth that reverses after AT. Obesity-related OSA and poor sleep quality are associated with insulin resistance and dyslipidaemia; treating OSA improves these metabolic parameters and contributes to weight management by normalising leptin and ghrelin regulation.
• Safety improvement in parasomnias: Effective management of sleepwalking with environmental modifications and scheduled awakenings dramatically reduces the risk of injury during somnambulistic episodes. Parental education about the benign, self-limiting nature of NREM parasomnias reduces unnecessary medical investigations and parental anxiety.
• Quality of life in narcolepsy: Although narcolepsy is a lifelong condition without a cure, pharmacological management of EDS and cataplexy, combined with structured naps and psychosocial support, substantially improves educational attainment, social participation, mental health, and independence. Early diagnosis — before years of unrecognised disability — is associated with better functional outcomes.

As with all paediatric medical and surgical interventions, treatments for sleep disorders carry risks that must be weighed carefully against their benefits:

• Residual OSA after adenotonsillectomy: The CHAT trial demonstrated that 27% of children with OSA had residual disease on post-operative PSG. Risk factors for residual OSA include obesity, severe pre-operative AHI, craniofacial abnormalities (retrognathia, midface hypoplasia), Down syndrome, and neuromuscular disease. All children with pre-operative AHI >10, obesity, or complex comorbidities should have post-operative PSG 6–8 weeks after AT; pre-operative AHI <10 in otherwise healthy children may be assessed clinically, with PSG reserved for symptomatic concerns.
• CPAP non-adherence and side effects: CPAP usage below 4 hours per night is associated with inadequate therapeutic benefit. Adverse effects include nasal congestion, mask leak, aerophagia (air swallowing), claustrophobia, and — with long-term use in growing children — midface hypoplasia from mask pressure on developing facial bones. Minimising mask interface pressure and regular mask resizing are important. Heated humidification reduces nasal side effects.
• Melatonin use in children: Melatonin is widely used in children with neurodevelopmental conditions and CRSD, but its long-term safety in developing children is not fully established. While short-term use is considered safe at doses of 0.5–5 mg, the UK MHRA licensed melatonin (Slenyto) for ASD-associated insomnia only in 2021; melatonin for other indications in children remains off-label in many countries. The theoretical concern that supraphysiological melatonin exposure could affect pubertal timing has not been confirmed in observational studies but warrants further long-term data.
• Sodium oxybate for narcolepsy — misuse potential: Sodium oxybate (GHB; Xyrem) is a Schedule II controlled substance with significant misuse potential. Prescribing requires specialist initiation, a central pharmacy registry (REMS programme in the USA; named patient basis in the UK), family education about secure storage, and clear guidance that it must never be combined with alcohol or CNS depressants. Despite these concerns, sodium oxybate is the most effective and guideline-recommended treatment for narcolepsy with cataplexy in eligible children.
• Planned scheduled awakening — sleep disruption: Scheduled awakenings for NREM parasomnia prevention require parents to wake the child 15–30 minutes before typical event times, which involves disrupting the parent's own sleep. It is most effective for children with consistent event timing and should be applied for a defined period (4–6 weeks) rather than indefinitely.
• CBT-I-A sleep restriction — initial worsening: The sleep restriction component of CBT-I-A temporarily increases daytime sleepiness in the first 1–2 weeks of treatment, which can affect school performance before improvement occurs. Adolescents and families must be warned and supported through this phase. School-based liaison (temporary timetable flexibility) can mitigate the impact.

Structured follow-up is essential across all paediatric sleep disorders to confirm treatment efficacy, monitor for complications, adjust management, and track developmental progress.

OSA follow-up:

• Post-adenotonsillectomy PSG at 6–8 weeks for all high-risk children (obesity, severe pre-operative AHI >10, craniofacial abnormality, Down syndrome, neuromuscular disease) and for any child remaining symptomatic after surgery
• CPAP adherence download review at 4–6 weeks post-initiation and then every 3–6 months; adherence data (AHI on device, hours used, mask leak) should be reviewed at each visit and barriers to adherence addressed
• Annual reassessment of the need for ongoing CPAP, particularly in obese children undertaking weight management and in children who have undergone significant growth (airway anatomy changes with growth may allow CPAP discontinuation in some)
• Annual ENT and orthodontic review in children with persisting craniofacial risk factors for OSA

CRSD follow-up:

• Repeat 2-week actigraphy at 6–8 weeks after initiating melatonin and light therapy to assess phase advance achieved
• Gradual stepwise earlier sleep timing (advancing target bedtime by 15 minutes per week) to consolidate circadian phase advance
• School liaison letter supporting modified start time where possible; there is growing evidence that delayed school start times for adolescents improve health and academic outcomes

Narcolepsy follow-up:

• 3-monthly reviews in the first year of treatment, assessing EDS severity (Epworth Sleepiness Scale), cataplexy frequency, medication tolerability, and school/social functioning
• Annual neuropsychological assessment to monitor academic performance and identify support needs
• Driving assessment planning from age 16: in the UK, a diagnosis of narcolepsy requires DVLA notification; driving may be permitted only when EDS is confirmed to be adequately controlled on treatment
• Transition to adult neurology and sleep medicine services at 16–18 years, with comprehensive handover documentation

Insomnia and parasomnias:

• CBT-I-A follow-up at 4 weeks and 8 weeks (end of active programme) with sleep diary review and relapse prevention planning
• Parasomnias: clinical review at 6 months to assess frequency and spontaneous resolution; re-evaluate if events escalate in frequency, become more prolonged, or are associated with injury risk

The costs of diagnosing and managing paediatric sleep disorders vary depending on condition complexity, diagnostic pathway, and healthcare system. Key cost considerations include:

• Polysomnography (PSG): Overnight in-laboratory PSG is the gold standard for diagnosing OSA and narcolepsy. In the UK NHS, overnight PSG is commissioned through respiratory or neurology specialist sleep services at no direct cost to the patient; private PSG in the UK costs approximately £1,500–£3,000 per study. In the United States, a paediatric in-laboratory PSG typically costs $1,500–$3,500. Home sleep testing (HST) devices are less accurate in children than adults and are generally not recommended for primary paediatric OSA diagnosis.
• Actigraphy: Wrist-worn actigraphy devices are substantially cheaper than PSG (device cost approximately £200–£500; some services lend devices at no cost). Actigraphy is highly cost-effective for CRSD diagnosis and CPAP adherence monitoring, replacing the need for multiple in-laboratory studies.
• Adenotonsillectomy: In the UK NHS, AT is a commissioned surgical procedure at no direct cost to the patient. Private AT costs approximately £3,000–£6,000 including anaesthesia and day-case surgical facility fees. In the United States, AT costs $5,000–$10,000 before insurance. Given the high prevalence of paediatric OSA and the proven neurobehavioural and quality-of-life benefits of AT, health economic analyses consistently find AT to be cost-effective compared with watchful waiting.
• CPAP equipment: A CPAP device with humidifier costs approximately £400–£800 for purchase; in the UK NHS, CPAP devices are provided on loan at no cost to the patient. Ongoing costs include mask replacements (£50–£200 per mask, typically replaced every 3–6 months), humidifier water, and CPAP filters. Annual CPAP total consumable costs are approximately £150–£400.
• Narcolepsy medications: Modafinil costs approximately £50–£200 per month. Sodium oxybate (Xyrem) costs approximately £10,000–£30,000 per year; it is commissioned through NHS England for confirmed narcolepsy type 1 with cataplexy. In the USA, sodium oxybate has list prices exceeding $10,000 per month, though manufacturer assistance programmes and insurance negotiations reduce patient costs substantially.
• CBT-I-A: Delivered by a trained clinical psychologist, CBT-I-A typically consists of 6–8 weekly sessions at approximately £100–£200 per session privately in the UK. In the NHS, CBT-I-A may be available through IAPT or paediatric psychology services at no cost, though waiting times can be significant. Digital CBT-I-A platforms (apps such as Sleepio) offer lower-cost alternatives with some evidence of efficacy in adolescents.

A range of non-pharmacological, complementary, and emerging alternative approaches play a role in managing paediatric sleep disorders, either as first-line therapies or as adjuncts when primary treatments are insufficient or declined:

• Watchful waiting for mild OSA (CHAT trial evidence): The CHAT trial enrolled children with AHI 2–30 events per hour and demonstrated that 46% of children in the watchful waiting arm showed normalisation of PSG parameters at 7 months without surgery, suggesting that mild OSA in otherwise healthy school-age children may resolve spontaneously with time. Watchful waiting is appropriate for mild OSA (AHI 2–5/hour) in children without neurobehavioural consequences, with repeat PSG in 6–12 months to confirm improvement. It is not appropriate for moderate-severe OSA or OSA with significant neurobehavioural impact.
• Mandibular advancement devices (MAD) and orthodontic approaches: Removable mandibular advancement splints that protrude the lower jaw during sleep expand the upper airway and reduce OSA severity. They are particularly useful in adolescents with mild-moderate OSA and retrognathia who are not suitable surgical candidates or who decline CPAP. Rapid maxillary expansion (RME) — an orthodontic device that widens the palate and nasal cavity — has been shown to improve OSA in children with high arched palate and nasal obstruction, with sustained benefit after device removal.
• Weight management for obesity-related OSA: In obese children and adolescents, weight loss through lifestyle intervention (dietary modification, physical activity) improves OSA severity significantly. A 10% reduction in body weight is associated with approximately 25% reduction in AHI. Structured paediatric obesity management programmes, integrating dietitians, physical activity specialists, and behavioural psychologists, are recommended alongside AT or CPAP for obese children with OSA.
• Positional therapy for OSA: Some children with OSA have predominantly supine-position-dependent apnoea (AHI at least twice as high supine vs lateral). Positional therapy — wearable devices or positional pillows that prevent supine sleeping — can reduce OSA severity and may be useful as a bridge or adjunct in mild cases, though evidence in children is limited compared with adults.
• Melatonin for neurodevelopmental conditions: Children with ASD, ADHD, and visual impairment frequently experience severe sleep initiation difficulties due to disrupted circadian biology. Low-dose melatonin (0.5–5 mg, 30–60 minutes before target bedtime) is the most evidence-based pharmacological adjunct for these groups, reducing sleep onset latency and improving total sleep time, with a favourable safety profile in short-to-medium term use. The UK-licensed Slenyto (prolonged-release melatonin 2 mg) is indicated for insomnia in children with ASD and/or Smith-Magenis syndrome aged 2–18 years.
• Mindfulness and relaxation for adolescent insomnia: Mindfulness-based stress reduction (MBSR) adapted for adolescents, progressive muscle relaxation, and app-based guided sleep meditation programmes (e.g., Headspace, Calm) have demonstrated modest improvements in sleep onset latency and subjective sleep quality in adolescent insomnia when delivered as standalone or adjunctive interventions. They carry no adverse effects and are appropriate as first-line adjuncts alongside sleep hygiene education.